Stock listing

Hanover:NP5 Newron Pharmaceuticals S.p.A. Aktie

German listing (Hanover) of Newron Pharmaceuticals S.p.A. · home listing SIX Swiss:NWRN

Follow Newron Pharmaceuticals S.p.A. into a list and get an email when it puts out news.

Home listing price · SIX:NWRN

7.97 CHF -0.23 (-2.8%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, SIX:NWRN

Since Jul 6, 2026 -33.4% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
7.90 – 8.29 CHFOct 19, 2026
Volume
38,250 sharesOct 19, 2026
Market value
163.0M CHFAt the close on Oct 19, 2026 · price × 20.45M shares outstanding
Newron Pharmaceuticals S.p.A. logo
Ticker
Hanover:NP5
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Hanover
Currency
EUR

What changed lately

Calls

Replays

  • Newron Pharmaceuticals (SIX Swiss: NWRN) Q4 2025 Earnings Call

    Tue, Mar 24, 2026 · 9:30 AM ET

    Watch Transcript

Latest news

Newron presents H1 2026 results and provides corporate update

Sep 22, 2026

Newron Pharmaceuticals S p A presents H1 2026 results and provides corporate update

Sep 22, 2026

Newron Reports Subscription for EUR 5.5 Million of Shares by Investor Group as Part of Up to EUR 38 Million Total Financing to Advance Phase 3 Evenamide Program

Sep 8, 2026

Newron Pharmaceuticals to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Sep 3, 2026

Newron announces completion of screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)

Sep 2, 2026

Newron Provides Update Following Type A Meeting With the FDA

Jul 2, 2026

Newron Pharmaceuticals to Participate in June Investor Conferences

May 28, 2026

Newron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 Study

Apr 29, 2026

Newron Announces AGM 2026 Results

Apr 23, 2026

Newron Presents 2025 Financial Results and Provides 2026 Outlook

Mar 24, 2026

All Newron Pharmaceuticals S.p.A. news

Financings

  • Private placement of newly issued shares

    Sep 22, 2026

    Tranche closed: €20.5M raised

    Use of proceeds: Strengthen financial position and support continued execution of the ENIGMA-TRS Phase 3 program for evenamide

    Tranche closed Sep 8, 2026 · Tranche closed Sep 22, 2026

Read by 6ix AI from the company's releases

Decks

Newron Pharmaceuticals S.p.A. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
23 in the last 12 months · 32 in all · newest Sep 22, 2026 · oldest 2025
Calls
1 call with a replay · 1 with a transcript · latest Mar 24, 2026
Decks
14 decks · latest Mar 24, 2026

Where Newron Pharmaceuticals S.p.A. is listed

ListingExchangeCountryCurrency
SIX Swiss:NWRN · Home listingSIX SwissSwitzerlandCHF
Xetra:NP5XetraGermanyEUR
gettex:NP5gettexGermanyEUR
LS Exchange:A0LF18LS ExchangeGermanyEUR
LSE:0QOILSEUnited KingdomCHF
Tradegate:NP5TradegateGermanyEUR
Lang & Schwarz:A0LF18Lang & SchwarzGermanyEUR
BX Swiss:NWRNBX SwissSwitzerlandCHF
OTC:NWPHFOTCUnited StatesUSD
Frankfurt:NP5FrankfurtGermanyEUR
Aquis:NWRNZAquisUnited KingdomCHF
Stuttgart:NP5StuttgartGermanyEUR
Hamburg:NP5HamburgGermanyEUR
Dusseldorf:NP5DusseldorfGermanyEUR
Munich:NP5MunichGermanyEUR
Turquoise:NWRNZTurquoiseUnited KingdomCHF
Hanover:NP5 · This pageHanoverGermanyEUR

Log in to ask 6ix AI your own questions about Newron Pharmaceuticals S.p.A.